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Abstract: Selective phosphodiesterase type 5 inhibitors (PDE5Is) have revolutionized the 
  treatment of erectile dysfunction (ED) in men. As an on-demand treatment, PDE5Is have excellent 
efficacy and safety in the treatment of ED due to a broad spectrum of etiologies. Nevertheless, 
these drugs do have side-effect profiles that are troublesome to some patients, eg, headache, 
dyspepsia, myalgia, etc. Furthermore, many patients and their partners dislike the necessity of 
on-demand treatment for ED, citing a desire for greater spontaneity with sexual interactions. 
In 2008, approximately 10 years after the release of the first commercially available PDE5I, a 
paradigm shift in the management of ED occurred with the approval of once-daily dose of tadalafil 
by the US Food and Drug Administration for the management of ED. The prolonged half-life 
of tadalafil lends itself well to this dosing regimen and conveys the advantage of separating 
medication from sexual interactions; lower dose therapy also carries the theoretical benefit of 
lower incidence of side effects. In this study, we review the current state of the art with respect 
to this new management strategy for ED, highlighting published reports of the efficacy and 
tolerability of the daily dose tadalafil regimen.
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Introduction
Erectile dysfunction (ED) is defined as the persistent and/or recurrent inability to attain 
and/or maintain a penile erection sufficient for satisfactory sexual intercourse.1 This 
problem is prevalent throughout the world and is strongly associated with   age-related 
comorbidities; hence, the incidence of ED will likely increase dramatically as the 
world’s population ages.2 ED is associated with substantial psychological distress 
for both men and their partners and has been clearly linked to cardiovascular health 
problems both as a comorbid condition and as a sentinel event for serious vascular 
diseases in the future.2–5
In this modern era, selective phosphodiesterase type 5 inhibitors (PDE5Is) are the 
mainstay of treatment for ED.6 These medications are highly efficacious, are well   tolerated, 
and have very favorable safety profiles. In the United States, 3 PDE5Is are currently 
available; sildenafil (Viagra®, Pfizer), vardenafil (Levitra®, Bayer), and tadalafil (Cialis®, 
Lilly-ICOS).7 Each of these drugs is highly efficacious in the management of ED although 
pharmacokinetic and side-effect profiles differ and results for each drug may vary for 
individual men.7,8 Another PDE5I, udenafil, has been approved for use in South Korea, 
and a number of novel PDE5Is are currently in various stages of development.9,10
Tadalafil was approved for use in the United States in November 2003, after both 
sildenafil and vardenafil were approved.11 Tadalafil differs from the other 2 PDE5Is Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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in that the absorption does not appear to be influenced by 
the intake of fatty meals or alcohol.11 Peak serum concentra-
tion is attained about 2 hours postdose rather than 1 hour as 
occurs with the other 2 PDE5Is.12 Tadalafil is also unique 
in that it has a long elimination half-life of approximately 
18 hours.13 The potential advantage of this prolonged dura-
tion of action is that the other medications can be separated 
temporally from sexual activity.14 The theoretical impact of 
this pharmacokinetic property is that sexual spontaneity may 
be more easily restored using this medication.15 However, the 
prolonged half-life of tadalafil also makes it more prone to 
long-lasting adverse effects (such as headache) relative to 
the other PDE5Is, with up to 30% of men on tadalafil treat-
ment reporting side effects lasting greater than 12 hours.16 
Importantly, chronic dosing of tadalafil has not been shown 
to lead to upregulation of PDE5 in human penile tissue,17 
an effect that has been observed in rat penile tissue exposed 
continuously to high doses of sildenafil.18 This difference 
may theoretically make tadalafil less likely than sildenafil to 
lose its efficacy over time due to tachyphylaxis.
There has long been a substantial interest in routine   dosing 
of PDE5Is as a new and novel approach to the management 
of ED. The advantage of daily dosing for management of ED 
is the complete separation of medication use from sexual 
activity.14,19 Furthermore, routine low-dose exposure may 
diminish overall drug exposure in men who engage in sexual 
intercourse more than twice weekly and may minimize side 
effects in men who have trouble tolerating higher doses of 
the PDE5I.19,20
The prolonged half-life of tadalafil makes it ideally 
suited for daily dosing and attainment of steady-state serum 
levels.21,22 In the multicenter, randomized, Scheduled Use 
versus on-demand Regimen Evaluation (SURE) study, 
4,262 men with ED were treated with 20 mg of tadalafil 
3 times weekly or 20 mg on-demand in a 12-week cross-over 
design. At follow-up, more than 60% of men in both arms 
reported normalization of erectile function. More than 70% of 
men in both groups reported ability to successfully penetrate 
and complete sexual intercourse relative to 21% at baseline. 
There were no differences in success rate between routine and 
on-demand dosing for any efficacy parameter.23 There was a 
substantial difference in the timing of intercourse between 
the treatment arms, with 53% of attempts in the on-demand 
arm and 29% of attempts in the routine dose arm occurring 
within 4 hours of dosing.24 This suggests that greater flex-
ibility with respect to timing was possible in the routine 
dose group. Although efficacy data did not demonstrate a 
difference, the 3 times a week dosing regimen for tadalafil 
was preferred only by 43% of enrolled patients.25 Although 
on-demand therapy was preferred by a majority of men, it 
was apparent that routine dosing was also a good option for 
a substantial minority of subjects.
The SURE study was 1 of the first of many studies investi-
gating the utility of chronic dosing for tadalafil. These efforts 
culminated, in 2008, in US Food and Drug Administration’s 
approval of tadalafil at a 2.5-mg or 5-mg daily dose for the 
management of ED.11,19 This paradigm shift in the manage-
ment of ED represented not only a new way to treat the 
condition but also a change in our conception of the disorder; 
ED is no longer strictly a situational problem in need of on-
demand treatment but rather is a chronic condition that can 
be managed with routine-dose pharmacotherapy.
In this study, we will discuss the current state of the art 
for daily dose of tadalafil in the management of ED from the 
studies published before April 2010. The particular areas of 
investigation will include safety, efficacy, and   compliance. 
Routine-dose tadalafil is also under investigation for a 
number of non-ED conditions;26–28 however, in the interest 
of conciseness, we will focus our attention on indications 
related to erectile function.
Methods
A literature review was conducted to obtain all publications 
pertaining to routine-dose tadalafil. The search terms used 
on PubMed included tadalafil, ED, daily dosing, routine 
dosing, and Cialis. Manuscripts were identified and selected 
based on their relevance to the subject matter of daily dose 
tadalafil for ED. Selected manuscripts were read and critically 
reviewed. Particular attention was directed to manuscripts 
based on randomized, double-blind, placebo-controlled 
studies (RDBPCSs).
Physiology of penile erection
To understand the action of PDE5 inhibitors, it is necessary 
to have some familiarity with the molecular mechanisms of 
penile erection. Briefly, sexual stimulation induces nitric 
oxide (NO) release from endothelial cells and   nonadrenergic 
and noncholinergic neurons. NO activates the cellular 
enzyme guanylate cyclase, which cleaves guanosine triphos-
phate into cyclic guanosine monophosphate (cGMP). cGMP 
in turn activates a series of downstream G proteins, which 
collectively lead to a decline in intracellular calcium content 
and subsequent smooth muscle relaxation. With muscular 
relaxation, there is a dilation of the cavernous arteries and 
corporal sinusoids of the penis, leading to enhancement of 
blood flow.29Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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PDE5 is the enzyme primarily responsible for the 
  hydrolysis of cGMP in the penis.30 Inhibition of PDE5 leads 
to persistent vasodilation and maintenance of penile blood 
flow by sustaining a high level of cGMP in the cavernous 
tissues and arteries.30 It is important to note that PDE5I do 
not spontaneously produce vasodilation; sexual stimulation 
is required for potentiation of erection with PDE5I. For this 
same reason, the efficacy of these drugs tends to be less in 
patients with conditions in which NO activity (and subse-
quent production of cGMP) is low or absent, such as diabetes 
or after pelvic surgery.31,32
Assessing efficacy of ED treatments
When interpreting data on efficacy in the ED literature, it is 
essential to be familiar with the existing validated instruments 
for assessment of treatment response. The International Index 
of Erectile Function (IIEF) is the most widely used quantitative 
validated scale for studies of ED treatments. Consisting of 15 
items covering 5 domains of male sexual function, it is most 
commonly utilized to assess the change in erectile function 
after treatment.33 Six items of the IIEF pertain directly to erec-
tile function and comprise the IIEF erectile function domain 
(IIEF-EF or IIEF-6; score range 5–30).33 A score of 26–30 
points on the IIEF-EF is generally consistent with normal 
erectile function, with progressively lower scores indicative of 
ED of worsening severity (22–25 = mild ED, 17–21 = mild to 
moderate ED, 11–16 = moderate ED, and #10 = severe ED).34 
Additional domains of sexual function assessed by the IIEF 
include sexual desire, intercourse satisfaction, orgasmic func-
tion, and overall satisfaction.33 Although similar but distinct 
instruments for the assessment of ED (such as the IIEF-5 or 
Sexual Health Inventory for Men) are also used in both clinical 
and research contexts, most studies of daily dose tadalafil to 
date are relied mostly on IIEF-EF domain scores.
The sexual encounter profile (SEP) questions are also 
common end points for studies of ED treatments.35 Designed 
as diary entries to be made after each attempt at sexual inter-
course, the SEP profile consists of 5 questions, each of which 
is primarily dependent on an affirmative response to the prior 
question. The SEP questions are in the following order – SEP1: 
“During sexual activity, did your penis become erect?” SEP2: 
“Whether you were able to insert your penis into your partner’s 
vagina?” SEP3: “Did your erection last long enough for you to 
have a successful intercourse?” SEP4: “Are you satisfied with 
the hardness of your erection?” SEP5: “Are you overall satis-
fied with this sexual experience?”35 Although the instruments 
are subjective in nature, they do encompass the efficacy of any 
given drug treatment in a simple “yes” and “no” fashion.
The IIEF and SEP questionnaires investigate sexual 
  function specifically. Different instruments must be utilized 
to assess the influence of ED treatment on relationship   factors 
and other interpersonal variables. The self-esteem and rela-
tionship (SEAR) quality survey is a validated tool for the 
assessment of the 2 domains of relationship quality: sexual 
relationship and confidence, which are further subdivided 
into SEAR quality subdomains.36 SEAR scores are typically 
normalized to a 0–100 range, with higher scores indicating 
better relationship functioning or confidence.36
Pharmacology of tadalafil
Tadalafil in a β-carboline-based type 5 phosphodiesterase 
inhibitor, with a piperazinedione ring formed from a modifi-
cation of the hydantoin ring seen on sildenafil.37 The molecu-
lar structure of tadalafil, a heterocyclic nitrogen-containing 
double-ring system with a central ring, mimics cGMP. 
This allows for competitive binding to the catalytic site of 
PDE5.37 Tadalafil is approximately 700 times more selective 
for PDE5 relative to PDE6 (the PDE isoform found in the 
retina).11 Furthermore, tadalafil has approximately 1/50th to 
1/100th the affinity of sildenafil or vardenafil for PDE6.38 This 
selectivity most likely underlies the much lower incidence of 
visual side effects from tadalafil as compared with the other 
commercially available PDE5Is.39 However, tadalafil does 
have relatively high affinity for PDE11, an isoform found 
in skeletal muscle, which is considered to be related to the 
higher incidence of myalgia and back pain in patients on 
tadalafil therapy relative to sildenafil and vardenafil.16
The prolonged half-life of tadalafil is due to the low 
volume of distribution, slow hepatic clearance, and approxi-
mately 80% bioavailability.11,12 Upon administration, it 
reaches the maximum plasma concentration in 2 hours. 
Although peak concentrations take 2 hours, the onset of 
action has been reported within 15 minutes of dosing and 
the efficacy may persist for up to 36 hours.15,40 It has been 
speculated that retention of PDE5I in cells but not serum and/
or continuation of cellular effects from PDE5I may lead to 
persistent erection-potentiating activity even after its serum 
levels have declined.41 Tadalafil is metabolized by CYP450 
3A4 to a catechol metabolite; subsequently, it is further 
metabolized to its circulatory metabolite, methylcatechol 
glucuronide. Excretion is primarily in feces, with about one-
third of the metabolized drug excreted in the urine.11
Tadalafil has linear pharmacokinetics over the dose range 
of 2.5–20 mg.12 A steady state of tadalafil is reached after 
5 days of daily administration, with a plasma concentration 
that is roughly 1.6 times higher than that of a single dose.12 In Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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other words, cumulative plasma exposure at steady state of a 
5-mg daily dose corresponds roughly to an 8-mg on-demand 
dose.42 In a study simulating pharmacokinetics of daily dose 
tadalafil, a dosage of 5 mg once daily was estimated to lead to 
a trough serum concentration of 55 ng/mL, which corresponds 
to 90% PDE5 inhibition in vitro. This therapeutic target is 
acknowledged to correspond with clinical efficacy of drugs 
and, therefore, serves as a reasonable surrogate marker for 
concentrations likely to produce an erectogenic effect.20 At 
steady state, the peak plasma concentration of 5 mg admin-
istered once daily is less than that of 10 or 20 mg taken 2–3 
times per week.20 It is implied from these data that men who 
experience side effects from higher serum concentrations of 
tadalafil may benefit from the lower peak concentrations seen 
with the daily dose therapy while sacrificing little in the way of 
efficacy. Interestingly, when daily dosing of 2.5–5 mg has been 
compared with on-demand dosing at 10–20 mg for tadalafil, the 
frequency of headaches has generally been 3–5 times less in 
the daily treatment arms.43 However, the caveat is that men who 
require greater serum concentrations for therapeutic effect (ie, 
those with more severe ED) may be better served by the higher 
peak concentrations obtained with on-demand dosing.
Certain substances known to inhibit CYP450 (such as 
ketoconazole, erythromycin, protease inhibitors, and grape-
fruit juice) may slow the excretion of tadalafil, and therefore, 
patients taking these should consider on-demand therapy 
exclusively or the lowest possible daily dose (2.5 mg).11 
Patients with hepatic impairment are also generally advised 
to start at the lowest dose possible; pharmacokinetic studies 
have suggested delayed excretion of the drug in patients with 
moderate or severe renal impairment.44 For patients with these 
conditions, therapy with on-demand tadalafil may be safer 
although low dose (2.5 mg daily) may be an option in some 
cases. Caution should also be exercised when prescribing 
daily dose of tadalafil to patients with a history of coronary 
artery disease. As nitrates are strictly contraindicated in 
patients on PDE5I, consideration must be given to the risk 
of administering a PDE5I with a prolonged half-life, which 
would tend to complicate standard therapy for angina symp-
toms.45 This important contraindication is due to the syner-
gistic effect of nitrates (an exogenous source of NO) coupled 
with decreased degradation of the NO downstream effector 
cGMP by PDE5I. This synergistic effect may lead to drastic 
decreases in blood pressure that could be life threatening.45
Efficacy of daily dose tadalafil
There have been numerous trials of tadalafil as a routine dose 
therapy. Many of the published reports have included analyses 
of existing older data sets with new statistical methods or 
primary outcome measures. A summary of all publications 
derived from RDBPCSs is presented in Table 1. Statistical 
significance is set at P # 0.05 for all of the studies detailed 
below unless otherwise noted.
McMahon 2004: daily tadalafil for ED
McMahon21 published one of the first reports of daily dose 
  tadalafil for ED in 2004. In this open-label flexible dose evalu-
ation, 112 men with ED of various causes who had failed to 
respond completely to 20-mg dosage of tadalafil on at least 
6 occasions and endorsed a SEP3 affirmative response rate 
of less than 30% were enrolled. These men were treated with 
20 mg of tadalafil on demand for 4 weeks, followed by a 
4-week washout period; they were subsequently treated with 
a 12-week, 10- or 20-mg flexible daily dose of tadalafil. One 
hundred and one men completed the study; there was a sub-
stantial improvement in mean IIEF-EF domain scores from 
10.3 at baseline to 14.9 after the 4-week on-demand treatment 
and to 23.1 after 12 weeks of daily dose therapy. The mean 
IIEF-EF domain score was significantly higher relative to both 
of the earlier time points after the daily dose phase. Affirma-
tive responses to SEP2 were 21% at baseline and increased to 
28% after on-demand therapy and 66%/62% for daily therapy 
with 10/20 mg, respectively. Affirmative responses to SEP3 
were 14% at baseline and increased to 21% after on-demand 
therapy and 58%/52% for daily therapy with 10/20 mg, 
respectively. Importantly, IIEF-EF domain scores normalized 
(.26) in 41% and 32% of men treated with daily dose therapy 
compared with none after the on-demand phase.21
McMahon 2005: daily tadalafil for ED
A follow-up, randomized, open-label cross-over trial by 
McMahon46 compared 12 weeks of tadalafil dose (10 mg daily 
vs 20 mg on-demand) in 145 men with ED of at least 6 months 
duration and SEP3 positivity less than 50%. Of them, 122 
completed the study. The baseline IIEF-EF score was 14.6; this 
score increased significantly to 23.3 and 26.4 at follow-up in 
the on-demand and daily dose arms, respectively. Affirmative 
responses to SEP2 were 36% at baseline and increased to 73% 
for on-demand therapy and 85% for daily therapy. Affirmative 
responses to SEP3 were 30% at baseline and increased to 67% 
for on-demand therapy and 80% for daily therapy. The IIEF-EF 
domain score   normalized (.26) in 57% and 73% of men 
treated with on-demand therapy and daily dose, respectively. 
Daily dosing was preferred by 72% of the patients compared 
with 28% preferring on-demand treatment.46Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 1 Efficacy of tadalafil once daily from randomized controlled trials
Study Design Subjects Treatment End points Findings
Porst et al42 RDBPCSs 293 men with 
$3 month  
history of eD
Tadalafil 5 mg  
or 10 mg daily  
for 12 wk
iieF-eF domain score, 
SeP2, SeP3
Tadalafil significantly 
improved eF relative  
to placebo regardless 
of baseline eD severity
Rajfer et al47 RDBPCSs 287 men with  
$3 month 
history of eD
Tadalafil 2.5 mg  
or 5 mg daily for  
24 wk
iieF-eF domain score, 
SeP2, SeP3
Tadalafil significantly 
improved eF relative 
to placebo regardless 
of baseline eD 
severity, with the 5 mg 
group experiencing 
numerically greater 
improvements than the 
2.5 mg group
Hatzichristou et al49 RDBPCSs 298 men with  
$3 month history  
of diabetes (type 1  
or type 2) and eD
Tadalafil 2.5 mg  
or 5 mg daily  
for 12 wk
iieF-eF domain score, 
SeP2, SeP3
Significant 
improvements in 
erectile function seen 
across all eD and 
diabetes subgroups 
treated with tadalafil
Porst et al48  1- and 2-y extensions  
of 2 RDBPCSs
234 men with eD who 
completed a 12-wk 
treatment period and 
238 men with eD who 
completed a 24-wk 
treatment period, all 
enrolled in open-label 
extensions
Tadalafil 5 mg  
or 10 mg daily  
for 12 wk, and  
tadalafil 2.5 mg  
or 5 mg daily  
for 24 wk
Safety: adverse event 
incidence, eCGs,  
clinical laboratory 
measures; efficacy:  
iieF-eF, -iS, -OS,  
GAQ1, GAQ2
No treatment-related 
serious adverse events 
or meaningful changes 
in clinical measures, 
normal eF attained by 
.50% of patients from 
both arms
Rubio-Aurioles et al52  RDBPCSs 342 men with  
$3 month history  
of eD and their  
female partners
Tadalafil 5 mg daily 
 for 12 wk
iieF-eF domain score, 
SeP2, SeP3, SQoL 
domain
Tadalafil-treated 
couples more likely 
to report sexual quality 
of life comparable  to 
what was experienced 
before eD onset
Seftel et al53  RDBPCSs 264 men with  
$3 month history  
of eD and their  
partners who met 
criteria for inclusion in 
this follow-up arm  
of this study
Tadalafil 5 mg daily  
for 12 wk
iieF-eF domain score, 
SeP2, SeP3, SQoL 
domain
Men treated with 
tadalafil had significant 
changes in eF, 
confidence, self-esteem, 
overall relationship, and 
partner’s satisfaction
Porst et al50  Post hoc analysis of a 
phase 2–3 RDBPCS
581 men with eD  
from study focused  
on BPH-LUTS
Tadalafil 2.5 mg, 5 mg, 
10 mg, or 20 mg daily 
for 12 wk
iieF-eF domain score, 
iPSS, peak urinary 
 flow rate, and  
postvoid residual 
volume
Tadalafil significantly 
improved iieF and iPSS 
scores independent of 
all other factors
Shabsigh et al35  Post hoc analysis of  
2 RDBPCSs
450 men with  
$3 month history  
of eD
Tadalafil 2.5 mg  
or 5 mg daily 
for 12 wk
Reliability (no. of “yes” 
responses to SeP3  
after initial attempt)
5 mg group had 
increased rates of 
reliability, intercourse 
success, and satisfaction
Abbreviations: eCG, electrocardiogram; eD, erectile dysfunction; eF, erectile function domain; GAQ1, Global Assessment Question 1; GAQ2, Global Assessment 
Question  2;  iieF,  international  index  of  erectile  Function;  iieF-eF,  international  index  of  erectile  Function-erectile  function  domain;  iieF-iS,  international  index  of 
erectile Function-intercourse satisfaction domain; iieF-OS,  international index of erectile Function-Overall satisfaction domain; iPSS, international Prostate Symptoms 
Score; RDBPCSs, randomized, double-blind, placebo-controlled studies; SEP, sexual encounter profile; SQoL, Sexual Quality of Life Domain of the Sexual Life Quality 
Questionnaire.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Porst 2006: daily tadalafil for ED
Porst et al42 evaluated the efficacy and safety of once-daily 
dosing of 5 and 10 mg tadalafil in a multicenter, parallel 
group RDBPCS of 293 men with ED, with treatment lasting 
12–15 weeks. The protocol was completed by 234 (87.3%) 
men, with medication compliance greater than 93%. Both 
the 5-mg and 10-mg doses significantly improved erectile 
function, with a mean change in IIEF-EF domain score 
of +9.7, +9.4, and +0.9 for the 5 mg, 10 mg, and placebo 
groups, respectively. The results remained similar when men 
with IIEF-EF domain scores within the range of normal 
(.26) at baseline were excluded. The mean percentage of per-
patient SEP2 affirmative responses was significantly higher in 
men in both the treatment arms (79.4%, 81.2%, and 51.7% for 
5 mg, 10 mg, and placebo groups, respectively). Similarly, the 
mean percentage of per-patient SEP3 affirmative responses 
was higher in treated men (67.2%, 72.8%, and 36.7% for 
5 mg, 10 mg, and placebo groups, respectively).42
Rajfer 2007: daily tadalafil for ED
Rajfer et al47 reported a multicenter, RDBPCS of tadalafil 
dosed at 2.5 or 5 mg daily vs placebo in men with ED over 
24 weeks. The protocol was completed by 238 men of the 287 
enrolled (83%). Tadalafil was found to be superior to placebo 
at both dosages for all primary efficacy end points; specifi-
cally, the mean IIEF-EF domain score increased by 6.1 and 
7.0 points in the tadalafil 2.5 and 5 mg arms, respectively, 
relative to an increase of 1.2 points in the placebo arm. The 
mean change in affirmative response to SEP2 was 24%, 
26%, and 5% for 2.5 mg, 5 mg, and placebo, respectively. 
The mean change in affirmative response to SEP3 was 31%, 
35%, and 10% for 2.5 mg, 5 mg, and placebo, respectively. 
Tadalafil also produced significant changes in other end points 
assessed by the IIEF, including intercourse satisfaction, sexual 
confidence, and overall satisfaction with sexual life.47
Porst 2008: daily tadalafil in 1- to 2-year 
open-label, follow-up studies
In a report on open-label extensions from 2 prior daily tadala-
fil trials,42,47 the mean IIEF-EF domain was found to improve 
from 13.7 at study baseline to 24.1 at the end of the 1-year 
extension and from 14.0 at baseline to 24.8 at the end of the 
2-year extension. Of interest, the mean IIEF-EF domain score 
declined to near-baseline level (16.0), following discontinu-
ation of tadalafil at the end of the 1-year open-label exten-
sion period. IIEF-EF domain scores of greater than 26 were 
attained by 58% of subjects in both the trials (117 of 202 and 
78 of 135 for the 1- and 2-year extensions, respectively). In 
the 1-year extension period, 114 of the 117 who normalized 
their erectile function continued into the ED treatment-free 
period; only 25% (28 of 114) maintained normal erectile 
function 4 weeks after discontinuing tadalafil. Only 3% 
(8 of 234) and 16% (39 of 238) of men in the 1-year and 
2-year open-label extension periods, respectively, discontin-
ued the treatment based upon a perceived lack of efficacy. The 
majority of men who discontinued had severe ED at baseline 
(7.5% [7 of 8] and 71.8% [28 of 39], respectively).48
Shabsigh 2010: reliability of daily tadalafil
Shabsigh et al35 reported on the reliability profile of tadala-
fil using data pooled from 2 prior studies42,47 of daily dose 
tadalafil vs placebo in men with ED. Reliability was defined 
as the rate of affirmative response to SEP3 after the initial 
attempt at intercourse after started receiving the study drug. 
Men in the 2.5 mg and 5 mg groups were significantly 
more likely to report successful intercourse (46% and 55%, 
respectively) on their initial attempt compared with 29% of 
men in the placebo group. Similarly, men in both the 2.5 mg 
and 5 mg groups were significantly more likely to report 
an affirmative response to SEP5 (overall satisfaction with 
sexual experience) relative to placebo-treated men (27%, 
39%, and 15%, respectively). Only the 5 mg group was 
significantly more likely to report affirmative response to 
SEP4 (satisfaction with erection hardness, 41%, 27%, and 
17% for 5 mg, 2.5 mg, and placebo groups, respectively) 
during their initial attempt.35
On analysis of subsequent attempts (the reliability 
analysis) at intercourse in all men who had initial success 
(affirmative SEP3), men in the 5 mg group (but not the 2.5 mg 
group) were significantly more likely to report consistent 
success relative to placebo-treated men (86%, 74%, and 70% 
in 5 mg, 2.5 mg, and placebo groups, respectively). However, 
men in both treatment arms were significantly more likely to 
endorse affirmative responses to SEP4 and SEP5 with repeat 
attempts than placebo-treated men. Among men with mild 
(IIEF . 17) or moderate ED (IIEF-EF 11–16), those treated 
with the 5-mg dose were significantly more likely to report 
successful intercourse on subsequent attempts; this effect was 
not noted for men with mild or moderate ED treated with 
2.5-mg dose, and no significant difference between dose and 
reliability was noted for men with severe ED (IIEF # 10).35
Among men who were unsuccessful on their first attempt 
at intercourse (negative SEP3), a significantly greater propor-
tion in both treatment arms reported affirmative response to 
SEP3 (52%, 58%, and 37% for 5 mg, 2.5 mg, and placebo 
among initial nonresponders) and SEP5 (49%, 52%, and 32% Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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for 5 mg, 2.5 mg, and placebo). The 5 mg group reported 
significantly greater SEP4 rates relative to placebo (54%, 
48%, and 34% in the 5 mg, 2.5 mg, and placebo groups, 
respectively). In contrast to what was observed for reliability 
in initial responders to tadalafil, in the initial nonresponders 
group, the 5-mg dose was significantly more likely to lead to 
successful subsequent intercourse than placebo, irrespective 
of baseline ED severity. Initial nonresponders (younger than 
65 years) were significantly more likely to report successful 
intercourse at both tadalafil dosages relative to placebo-treated 
men (younger than 65 years). There were no significant dif-
ferences in the rate of response in men older than 65 in this 
cohort, but the relatively small sample size for this age group 
in the non-initial responder group (n = 35 among 3 arms) 
likely underlies the failure to attain statistical significance.35
Hatzichristou 2008: daily tadalafil 
in diabetic men
Hatzichristou et al49 investigated the efficacy of daily dose 
tadalafil (2.5 and 5 mg) in diabetic men with ED in a multi-
center, 24-week RDBPCS. The protocol was completed by 
254 men of the 298 enrolled (85% completion). Tadalafil was 
found to be significantly superior to placebo at both dosages 
for all primary efficacy end points; specifically, the mean 
IIEF-EF domain score increased by 4.8 and 4.5 points in the 
tadalafil 2.5 and 5 mg arms, respectively, relative to a 1.3 point 
increase in the placebo arm. The mean change in affirmative 
response to SEP2 was 20%, 29%, and 5% for 2.5 mg, 5 mg, 
and placebo groups, respectively. Mean change in affirmative 
response to SEP3 was 26%, 25%, and 8% for 2.5 mg, 5 mg, 
and placebo groups, respectively.   Tadalafil also produced 
significant changes in other end points, including intercourse 
satisfaction, sexual confidence, and overall satisfaction with 
sexual life. This study also investigated serum biomarkers 
for diabetes (hemoglobin A1c) and inflammation, includ-
ing C-reactive protein, nitrotyrosine, intracellular adhesion 
molecule-1, and vascular adhesion molecule-1. No significant 
changes were noted for these serum parameters.49
Porst 2009: tadalafil for lower urinary 
tract symptoms, effects on erectile 
function
Porst et al50 published a post hoc analysis of sexually active 
men from a phase 2–3, multinational RDBPCS in men with 
ED and lower urinary tract symptoms (LUTS), considered to 
be secondary to benign prostatic enlargement, who were given 
placebo, 2.5 mg, 5 mg, 10 mg, or 20 mg tadalafil daily for a 
12-week treatment period. Of the 581 subjects who started the 
study, 85% completed the entire protocol. Although the focus 
of this investigation was on LUTS, IIEF-EF domain scores 
were noted to improve significantly at all time points (4, 8, and 
12 weeks), with mean change from baseline at the 12-week 
time point +5.4 ± 1.0 for 2.5 mg group, +6.8 mg ± 1.0 for 
5 mg group, +7.9 ± 1.0 for 10 mg group, and +8.2 ± 1.0 for 
the 20 mg group vs +2.0 ± 1.0 for placebo. Importantly, the 
frequency of sexual intercourse attempts was not significantly 
different between the treatment groups throughout the study. 
No significant differences in response were noted between 
various subgroups stratified by baseline age, body mass 
index, LUTS severity, serum prostate-specific antigen value, 
prior α-blocker use, and prior ED therapy. Among men with 
IIEF-EF scores less than 26 at baseline, normalization of 
IIEF-EF domain scores was attained at the conclusion of the 
study in 21.2% (24/113), 34.2% (40/117), 42.5% (51/120), 
40.0% (46/115), and 14.0% (16/114) of men in the 2.5 mg, 
5 mg, 10 mg, 20 mg, and placebo groups, respectively, with 
no explicit comment made on statistical significance in this 
study. Tadalafil appeared to have beneficial effects on LUTS 
severity at all dosages although this was not associated with 
any clinically significant changes in objective urodynamic 
parameters (urine flow rate and postvoid residual [PVR] urine 
volume), with the exception of a statistically significant (but 
likely clinically meaningless) increase in PVR volume in the 
2.5 mg group relative to the placebo group.50
Partner preference studies
The impact of tadalafil daily dosing on female partners’ 
  satisfaction with sexual activity has also been a topic of 
recent interest and research. A partner preference study of 
on-demand sildenafil vs tadalafil indicated that 79% of female 
partners preferred tadalafil, citing a more relaxed approach to 
sexual intimacy and greater flexibility with respect to timing 
of intercourse.51 Based on this, it may be inferred that the 
flexibility of completely separating medication from sexual 
activity (as is the case for daily dose therapy) would be 
appealing to many female partners of men with ED.
Rubio-Aurioles 2009: patients’ or 
partners’ satisfaction with daily tadalafil
Rubio-Aurioles et al52 reported on partners’ satisfaction in a 
multicenter, parallel group RDBPCS of 5 mg tadalafil daily 
vs placebo for 12 weeks for men with ED, most of whom had 
the condition for more than 1 year. A total of 342 couples 
were enrolled, and 307 couples (90%) completed the 12-week 
protocol. Of note, partners were prescreened using the Female 
Sexual Function Index (FSFI); partners with FSFI total scores Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
166
Washington and Shindel
less than 26.55 (suggestive of high risk of female sexual 
dysfunction) were excluded from the subsequent analysis. 
Mean IIEF-EF score at baseline was 15.8 and 15.1 in the 
tadalafil and placebo arms, respectively. Approximately, 
half of each group had mild ED (IIEF-EF score of 17+) at 
baseline. Men treated with tadalafil endorsed significantly 
greater improvements in IIEF-EF score (+7.9 vs +0.7 in the 
treatment and placebo groups) and changed to an affirmative 
response to SEP2 (29% and 3%, respectively) and SEP3 (46% 
vs 11%, respectively). Men and their partners in the treatment 
group reported significantly greater improvements in sexual 
quality of life and quality of treatment relative to placebo-
treated couples based on validated instruments. With respect 
to specific facets of sexual life, patients and partners treated 
with tadalafil reported greater frequency of sex, duration of 
sex, ease of penile insertion, ease of achieving orgasm, ease 
of initiating sex, pleasure of anticipation, carefree feelings 
during sex, pleasure with orgasm, overall pleasure, and 
perception of partner’s overall pleasure.52
Seftel 2009: treatment satisfaction  
and improvement in relationship quality 
in couples treated with daily tadalafil
In a follow-up data set based on the prior work reported by 
Rubio-Aurioles et al,52 Seftel et al53 reported on variables 
pertaining to overall sexual satisfaction in tadalafil-treated 
men and their female partners. Men who received tadalafil 
were significantly more satisfied with treatment compared 
with placebo (75% vs 51%, respectively), as measured by 
the sexual life quality questionnaire; female partners also 
endorsed significantly greater satisfaction with tadalafil as 
opposed to placebo (73% vs 55%, respectively). There was 
a significantly greater change in mean sexual life quality in 
the tadalafil-treated men relative to controls (+39 vs +12, 
respectively) and in female partners of treated men relative to 
partners of controls (+32 vs +5, respectively). The percentage 
of affirmative responses to SEP4 and SEP5 was significantly 
greater in the tadalafil group (57% and 56%, respectively) 
compared with placebo group (20% and 20%, respectively), 
when all intercourse attempts were considered. When only 
“successful intercourse attempts” (defined as affirmative 
response to SEP3) were considered, subjects in the tadalafil 
group reported significantly more affirmative responses to 
SEP4 and SEP5 (77% and 74%, respectively) relative to pla-
cebo group (56% and 52%, respectively). The mean increase 
from baseline intercourse satisfaction and overall satisfaction 
(as determined by the IIEF) was significantly greater in the 
tadalafil group (+3 and +3, respectively) vs placebo group 
(+0.5 and +0.1, respectively).53 Tadalafil-treated men also 
manifested significantly greater improvements on SEAR 
domains relative to placebo-treated men, with mean change 
in self-esteem of +34 vs +5 and mean change in confidence 
of +25 vs +3, respectively. Changes in IIEF-EF scores in 
the tadalafil and placebo arms positively correlated with all 
SEAR domains.53 The partners of tadalafil-treated men were 
on the whole more likely to report an affirmative response to 
the partner SEP3 question relative to the control men (70% vs 
37%, respectively). More importantly, improvements in the 
IIEF-EF of tadalafil-treated men were positively correlated 
to the satisfaction with treatment in their female partners.53
Althof 2010
Althof et al54 combined the results of the studies on 5-mg 
daily dosage of tadalafil (n = 473 couples) by Rubio-Aurioles 
et al52 and Porst et al42 to verify that daily dose tadalafil has 
a high degree of efficacy in managing ED and improving 
sexual quality of life for both patients and partners.54 There 
was strong concordance between both patients’ and partners’ 
assessment of erection, penetration capacity, and overall 
sexual satisfaction.54
Summary statement of efficacy
It is clear from numerous high-quality studies that tadalafil 
as a daily dose is highly efficacious in the management of 
ED from a variety of causes. It is also clear that daily dose of 
tadalafil will have a beneficial effect on the sexual relation-
ship between partners.
Side-effect profile of daily dose 
tadalafil
Side effects from daily dose tadalafil in clinical trials have 
generally been mild, with 54%–80% of reported events mild in 
nature and with no more than a third of events moderate 
in severity.21,42 Serious side effects have not been reported 
in some studies; in studies where serious events occurred, 
the effect was considered not to be related to the study drug 
itself.42,52 Although the effects may be mild, it should be noted 
that the prolonged half-life of tadalafil may tend to produce 
side effects of longer duration compared with PDE5I with 
shorter half-lives.16 Steady-state kinetics have been observed 
in daily dose tadalafil, with the steady-state levels being 
roughly 1.6 times greater than those of a single dose. Although 
this might lead to a greater incidence of side effects, this dos-
ing regimen may permit lower dosing overall.19,20 A summary 
of reported incidence of the most commonly reported side 
effects in RDBPCSs is presented in Table 2.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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In a report on open-label extension of tadalafil, 53% 
of subjects reported at least 1 adverse event in 1 year and 
73% within 2 years of therapy.48 Generally, the incidence of 
these side effects declines over time on chronic therapy.48 
The rate of consistent bothersome side effects (headache, 
back pain, dyspepsia, etc) of on-demand therapy with 
tadalafil has not been measured to be greater than 10%.43 
Discontinuation rates due to the side effects of medica-
tion are reportedly between 1% and 6%21,42,46–48,52 although 
higher rates of discontinuation (∼10%) have been reported 
in studies in which men received 20 mg of tadalafil daily 
for months on end.55
The most common side effects of daily dose tadala-
fil include headache (1%–14%), dyspepsia (1%–11%), 
facial flushing (7%–8%), nasal congestion (6%–7%), 
back pain (2%–11%), myalgias (1%–5%), abdominal pain 
(3%–9%), and dizziness (1%–4%).21,42,46,47,52 In some stud-
ies, side effects were more common at higher dosages of 
tadalafil,42,49,55 but this dose–response relationship was not 
confirmed in every study.21,50 In at least 1 study, there was 
no significant difference in the rate of side effects between 
the treatment and the placebo arms,52 but other studies 
suggested that flushing, dyspepsia, back pain, abdominal 
pain, and myalgia were more frequent with tadalafil than 
placebo.42,49,50
Tadalafil and hemodynamics
Tadalafil has been shown to have a favorable cardiovascular 
risk profile, with no significant indications of worsening isch-
emia, unstable hemodynamics, electrocardiogram changes, 
worsening of clinical laboratory parameters, or increase 
in serious cardiovascular events in men using the drug or 
placebo.11,20,47,48 Tadalafil has not been shown to be associ-
ated with QT prolongation.56 There have been no reports 
of increased mortality in men on tadalafil.11 It is important, 
however, to reemphasize that the nitrate use is a strict con-
traindication to PDE5I therapy.45
In 2 small randomized controlled trials of short (,1 month) 
duration, the influence of daily dose of 5 mg tadalafil on hemo-
dynamic parameters in healthy men given α blockers (doxazosin 
or tamsulosin; n = 45 and 39, respectively) was assessed. There 
was essentially no change in the mean standing systolic blood 
pressure or the heart rate between placebo- and tadalafil-treated 
men on either α blocker. One man, in both the tamsulosin and 
the doxazosin 4-mg arms experienced a standing systolic blood 
pressure of ,85 mm Hg while taking tadalafil; this rate did not 
differ significantly from what was observed in placebo-treated 
men.57 Generally, studies have been congruous with this one, 
suggesting a very low rate of clinically significant hypotension 
with tadalafil with or without α blockers; this effect held true 
regardless of the dosing regimen (on-demand, daily, etc).58
Table 2 Side-effect profile
Study Headache Dyspepsia Back pain Myalgia
McMahon et al21 8.7% (10 mg) 
13.6% (20 mg) 
16.1% (on-demand)
8.7% (10 mg) 
6.1% (20 mg) 
9.8% (on-demand)
4.3% (10 mg) 
4.5% (20 mg) 
6.3% (on-demand)
0% (10 mg) 
4.5% (20 mg) 
4.5% (on-demand)
McMahon et al46 8.0% (10 mg daily) 
17.1% (20 mg as-needed)
10.7% (10 mg daily) 
12.9% (20 mg as-needed)
6.7% (10 mg daily) 
4.3% (20 mg as-needed)
4.0% (10 mg daily) 
4.3% (20 mg as-needed)
Porst et al42 6.4% (5 mg) 
10.5% (10 mg) 
7.4% (placebo)
5.5% (5 mg) 
11.4% (10 mg) 
3.7% (placebo)
3.7% (5 mg) 
9.5% (10 mg) 
3.7% (placebo)
2.8% (5 mg) 
6.7% (10 mg) 
0.0% (placebo)
Rajfer et al47 3.1% (2.5 mg) 
1.0% (5 mg) 
3.2% (placebo)
4.2% (2.5 mg) 
1.0% (5 mg) 
1.1% (placebo)
5.2% (2.5 mg) 
2.1% (5 mg) 
3.2% (placebo)
4.2% (2.5 mg) 
1.0% (5 mg) 
2.1% (placebo)
Hellstrom et al55 16% (20 mg) 
2% (placebo)
8% (20 mg) 
1% (placebo)
11% (20 mg) 
3% (placebo)
8% (20 mg) 
1% (placebo)
Donatucci et al43
  1-y extension phase 9% 9% 7% –
  2-y extension phase 2% 4% 5% –
Porst et al48
  1-y extension phase 9.0% 9.0% 6.8% –
  2-y extension phase 2.1% 3.8% 5.0% –
Porst et al50 3.5% (2.5 mg)  
3.4% (5 mg)  
5.0% (10 mg) 
1.7% (20 mg) 
3.5% (placebo)
0.9% (2.5 mg)  
4.3% (5 mg)  
1.7% (10 mg)  
2.6% (20 mg) 
0% (placebo)
1.8% (2.5 mg)  
0.9% (5 mg)  
4.2% (10 mg)  
5.2% (20 mg) 
0.9% (placebo)
1.8% (2.5 mg)  
0.9% (5 mg)  
3.3% (10 mg)  
2.6% (20 mg) 
0% (placebo)Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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In an open-label extension of 2 prior trials of daily dose 
tadalafil, no clinically significant abnormalities on electrocar-
diogram or laboratory measures were observed in the general 
population of men on tadalafil. Of 472 men who participated, 
36 subjects (8% of total) reported serious adverse effects, 
which resulted in hospitalization, life-threatening complica-
tions, or disability. In 9 of these 36 subjects, (25%) a total of 
10 cardiovascular events occurred, including cerebrovascular 
accident, coronary artery disease, myocardial infarction, 
atrial fibrillation, worsening of hypertension, angina, and 
syncope. Eight of these occurred in patients with prior car-
diac histories. None of these adverse effects was considered 
tadalafil-related by the authors.48
Ophthalmology effects of daily dose 
tadalafil
A study of ophthalmological effects of daily placebo vs daily 
dose tadalafil (5 mg) or sildenafil (50 mg) in 244 subjects (194 
of whom completed the 6-month protocol) detected a sig-
nificantly higher increase in β-wave amplitude during elec-
troretinographic response to flash in light-adapted eyes for 
tadalafil relative to placebo. There were no other significant 
differences in the rate of ophthalmological abnormality or in 
the morbidity from drug treatment at study conclusion and 
4–6 weeks after cessation of treatment. Additional param-
eters assessed included the combined electroretinographic 
response to flash after darkness adaptation, visual acuity, 
color discrimination, visual-field testing, and intraocular 
pressure. The only ophthalmological adverse event was a 
retinal artery occlusion in 1 patient in the placebo arm.38 
Based on the relatively similar results, the authors concluded 
that there is no evidence to suggests clinically relevant side 
effects from this daily dose regimen.
Daily tadalafil and semen parameters
In the largest and longest duration study of tadalafil and its 
affect on male reproduction, Hellstrom et al55 investigated the 
influence of high-dose (20 mg) daily tadalafil for 9 months, 
with a 6-month follow-up in men older than 45 years of 
age. All men enrolled had normal values for testosterone, 
gonadotropins, and semen parameters that were within the 
World Health Organization reference ranges. This double-
blind, placebo-controlled, randomized, noninferiority trial 
enrolled 253 men, 191 (75%) of whom completed the 
9-month protocol and 179 (70%) of whom completed the 
6-month follow-up. The geometric mean sperm concentration 
was significantly lower in tadalafil-treated men at 9-month 
follow-up, 54.3 M/mL vs 63.4 M/mL in placebo, although 
after adjustment for multiple comparisons, the difference 
was no longer strictly significant (P = 0.06) and was not 
apparent after 6-month wash-out. A 50% decline in sperm 
concentration was reported in 2 (2%) of placebo-treated men 
compared with 12 (13%) of tadalafil-treated men at 9-month 
follow-up. Although the difference was substantial, it did not 
meet the criteria for inferiority given the upper 95% confi-
dence interval for proportion of subjects with a greater than 
50% decline on concentration was 17.5%, less than the 20% 
prescribed for inferiority. Interestingly, the mean ejaculatory 
frequency was significantly higher in men who experienced 
a greater than 50% drop in sperm concentration compared 
with those who did not (5.4 times per week vs 2.9 times per 
week, respectively). After 6 months of drug wash-out, sperm 
concentrations returned to baseline in 8 of 12 men treated 
with tadalafil and 1 of 2 treated with placebo.55 Fertility 
may not be a concern for many men taking tadalafil, and the 
study by Hellstrom et al55 did not conclusively demonstrate 
a negative influence on sperm parameters; indeed, it is pos-
sible that the much higher ejaculatory frequency in men who 
experienced a greater than 50% decline in sperm concentra-
tion was responsible for the results observed. Furthermore, 
the doses used in this study were much higher than those 
recommended for daily dose therapy. Be that as it may, the 
trend toward a decline in sperm concentration in some men 
is of note and should be kept in mind by men taking tadalafil 
who are concerned about conceiving children.
Daily tadalafil and serum androgen levels
In the study of semen parameters by Hellstrom et al,55 it was 
determined that the mean change in serum testosterone after 
9 months of daily dose tadalafil (20 mg) was significantly 
higher in the treatment group relative to the placebo group 
(P = 0.01 before adjustment and P = 0.03 after adjustment 
for multiple comparisons). Mean serum of luteinizing hor-
mone (LH) was also significantly higher (P = 0.05) in the 
treatment group at the 9-month time point; this relationship 
was not significant after the adjustment for multiple compari-
sons (P = 0.21). Free testosterone level was not found to be 
affected by the treatment.55 Although strict clinical and statis-
tical significance for difference in serum testosterone was not 
met, it is somewhat intriguing to speculate that tadalafil might 
have some sort of impact (either direct or indirect) on testos-
terone levels by a centrally mediated mechanism involving 
LH secretion because of the absence of a local effect on the 
testes themselves as noted by the authors.55 Although this 
explanation is strictly hypothetical, enhancement of erectile 
and sexual functions may have led to secondary changes Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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in neurochemical modulation of testosterone secretion by 
psychogenic mechanisms. To our knowledge, this effect has 
not been confirmed and this finding may be worthy of further 
investigation and verification.
Miscellaneous and potential  
side effects of tadalafil
Although the clinical relevance is not entirely clear, a single 
20-mg dose has been shown to produce detectable electro-
encephalographic changes in up to 34% of healthy men.59 
Animal studies have demonstrated a blunting of the cerebral 
vasoconstrictive response to hyperbaric oxygen therapy and 
subsequent lowering of seizure threshold in tadalafil-treated 
rats.60 The clinical relevance of these findings is unclear, but 
these may be important topics for future research. PDE5Is 
have also been associated with sudden sensorineural hear-
ing loss,61 and studies of audiometric properties in men and 
experimental animals using sildenafil or vardenafil have 
suggested changes in hearing.62,63 Although we are not 
aware of any published studies directly linking tadalafil to 
hearing changes, the possibility of a PDE5I class effect on 
hearing must be considered and taken seriously by patients 
and providers.
Future directions for daily dose  
tadalafil therapy
“Penile rehabilitation” refers to treatments intended to 
restore functional penile erection after some sort of physi-
ological insult, typically radical pelvic surgery; PDE5Is are 
the mainstay of penile rehabilitation therapy at present.64,65 
There exists substantial controversy regarding the true 
efficacy of penile rehabilitation, with the largest multicenter 
trial, to date, suggesting no long-term impact with the 
PDE5I vardenafil as either a routine or on-demand treatment 
despite several smaller studies of other PDE5Is suggesting 
benefit.66–68
Although the clinical efficacy of PDE5I for penile reha-
bilitation remains open to debate, basic science research has 
generally indicated favorable outcomes in animal models.69,70 
Tadalafil seems a logical choice for rehabilitative therapy 
given its prolonged duration of action; if indeed PDE5I 
exerts a protective or salubrious effect on penile tissues, a 
prolonged duration of exposure seems most likely to produce 
the desired results. When consulting basic science literature 
on PDE5I, it is important to recognize that the metabolism 
of PDE5I in rodents is much more rapid than in humans, and 
hence, proportionally large doses must be given to determine 
the therapeutic effects.71
A 2006 study of rats treated with 2 mg/kg tadalafil daily 
for 3 months after cavernous nerve transection (a model 
system for radical pelvic surgery induced ED) indicated 
that treated rats had superior erectile hemodynamics, 
as assessed by cavernous nerve electrostimulation with 
  real-time   measurement of intracavernous pressure. Molecu-
lar studies indicated that declines in erectile function after 
cavernous nerve injury were associated with the decreased 
smooth muscle to collagen ratio in the corporeal tissues 
and   evidence of hypoxia. Tadalafil treatment was found to 
ameliorate the decline in smooth muscle to collagen ratio 
and to restore oxygenation; this was associated with superior 
vasodilatory activity of tissues obtained from treated rats for 
in vitro   studies. The authors theorized that the maintenance 
of corporeal oxygenation is the underlying mechanism of 
action in the tadalafil-treated group.72
A similar study of daily dose tadalafil administered 
retrolingually (5 mg/kg/d) vs placebo in rats subjected to 
cavernous nerve transection indicated that treated rats had 
greater erectile response to papaverine and maintenance of 
normal veno-occlusive capacity during penile caverson-
ometry 45 days after injury, signifying less venous leak. 
Treated animals also had greater content of smooth muscle, 
less collagen deposition, and lower levels of apoptosis, all 
suggestive of better tissue integrity.73
The majority of published reports on penile rehabilitation 
to date have been on the other 2 PDE5Is that are commercially 
available. However, in 1 small, open-label human trial, tadalafil 
was investigated as a penile rehabilitation agent. Twenty men 
with ED were randomized to 20 mg of tadalafil either every 
other day or on demand (maximum 8 doses per month) for 
4 weeks in an open-label cross-over fashion. At 4-week 
follow-up, a significant increase (+8.3%) was noted in mean 
flow-mediated dilation of the cavernous artery in the every 
other day group. Furthermore, the mean peak systolic blood 
pressure in the flaccid state was also significantly increased in 
the every other day group. On the molecular level, every other 
day treatment led to significant declines in vascular cellular 
adhesion molecule, C-reactive protein, and endothelin-1, all of 
which are known to be associated with vasoconstriction and/
or inflammation. None of these theoretically beneficial effects 
was observed in the on-demand portion of the study.74
Although the evidence at this time is scanty, it is tantalizing 
to speculate that daily therapy with a PDE5I such as tadalafil 
may produce beneficial humoral and tissue effects, which tend 
to be erection protective. More research is required to deter-
mine what role these drugs may play in maintenance of sexual 
health rather than simple treatment of sexual problems.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
170
Washington and Shindel
Conclusion
Tadalafil is the first ED treatment approved for daily dosing. 
This represents an important change in our conception of 
ED as a disorder and has the potential to dramatically alter 
the way we approach this prevalent and vexing concern. 
Although not necessarily the optimal management schema 
for every man with ED, this exciting dosing option has the 
potential to expand our capacity to care for men with ED in 
a novel and unprecedented direction.
Disclosure
Alan W Shindel has served as a nonfiduciary consultant for 
Boeheringer-Ingelheim.
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